– Acquired Significantly Below Replacement Cost –
– Property Provides Long-Term Repositioning Opportunity –
– 2026 Year-to-Date Investments Total $334 Million –

WINTER PARK, Fla., Sept. 14, 2026 (GLOBE NEWSWIRE) — CTO Realty Growth, Inc. (NYSE: CTO) (the “Company” or “CTO”) today announced the acquisition of Zona Rosa, a 768,000 square foot mixed-use center located in Kansas City, Missouri, for $63.3 million, or $82 per square foot. The Company believes the combination of strong market demographics combined with its proven expertise to extract meaningful value from prior repositioning executions will provide the opportunity to produce a compelling initial yield and long-term return.

“With the addition of this new property, our year-to-date property acquisition volume now exceeds $200 million at a blended entry cash cap rate of 8.2%, and, with structured investments, activity totals $334 million at a blended initial cash yield of 9.5%,” said John P. Albright, President and Chief Executive Officer of CTO Realty Growth, Inc. “Zona Rosa is a leading mixed-use center located in one of Kansas City’s fastest-growing neighborhoods, ringed by average household income levels of $124,000 within 5 miles.”

Zona Rosa will be a long-term, multi-phase revitalization opportunity with substantial embedded upside via leasing and repositioning opportunities. The property is currently 67% leased, anchored by Dick’s Sporting Goods, Barnes & Noble, Old Navy, Burlington, and DSW. The 768,000-square foot, 64-acre center includes 10 acres of entitled development land and approximately 100,000 square feet of underutilized space for future value-add repositioning.

Zona Rosa is a leading retail, dining, and entertainment destination serving Kansas City’s Northland, with no comparable center within a 20-minute drive, attracting approximately 5.5 million visits annually. The property is located six miles from Kansas City International Airport, which recently completed a $1.5 billion new terminal, and its five-mile trade area has a population of approximately 100,000.

About CTO Realty Growth, Inc.

CTO Realty Growth, Inc. owns and operates high-quality, open-air shopping centers located primarily in the higher growth Southeast and Southwest markets of the United States. CTO also externally manages and owns a meaningful interest in Alpine Income Property Trust, Inc. (NYSE: PINE), a publicly traded net lease REIT.

We encourage you to review our most recent investor presentation and supplemental financial information, which is available on our website at www.ctoreit.com.

Safe Harbor

Certain statements contained in this press release (other than statements of historical fact) are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements can typically be identified by words such as “opportunity,” “upside,” “outlook,” “believe,” “estimate,” “expect,” “intend,” “anticipate,” “will,” “could,” “may,” “should,” “plan,” “potential,” “predict,” “forecast,” “project,” and similar expressions, as well as variations or negatives of these words. Statements, among others, relating to the opportunity for a compelling initial return and substantial embedded upside for Zona Rosa and potential earnings growth through lease-up, long-term redevelopment opportunities are forward-looking statements.

Although forward-looking statements are made based upon management’s present expectations and beliefs concerning future developments and their potential effect upon the Company, a number of factors could cause the Company’s actual results to differ materially from those set forth in the forward-looking statements. Such factors may include, but are not limited to: the Company’s ability to remain qualified as a REIT; the Company’s exposure to U.S. federal and state income tax law changes, including changes to the REIT requirements; general adverse economic and real estate conditions; macroeconomic and geopolitical factors, including but not limited to inflationary pressures, interest rate volatility, ongoing geopolitical war, distress in the banking sector, and global supply chain disruptions, and ongoing geopolitical war; credit risk associated with the Company investing in commercial loans, preferred equity, and similarly structured investments; the ultimate geographic spread, severity and duration of pandemics such as the COVID-19 Pandemic and its variants, actions that may be taken by governmental authorities to contain or address the impact of such pandemics, and the potential negative impacts of such pandemics on the global economy and the Company’s financial condition and results of operations; the inability of major tenants or borrowers to continue paying their rent or obligations due to bankruptcy, insolvency or a general downturn in their business; the loss or failure, or decline in the business or assets of PINE; the completion of 1031 exchange transactions; the availability of investment properties that meet the Company’s investment goals and criteria; the uncertainties associated with obtaining required governmental permits and satisfying other closing conditions for planned acquisitions and sales; and the uncertainties and risk factors discussed in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2025 and other risks and uncertainties discussed from time to time in the Company’s filings with the U.S. Securities and Exchange Commission.

There can be no assurance that future developments will be in accordance with management’s expectations or that the effect of future developments on the Company will be those anticipated by management. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. The Company undertakes no obligation to update the information contained in this press release to reflect subsequently occurring events or circumstances.

CONTACT: Contact:
Investor Relations
ir@ctoreit.com

TAIPEI, Taiwan, Sept. 14, 2026 (GLOBE NEWSWIRE) — Asia Pacific Wire & Cable Corporation Limited (NASDAQ: APWC) (“APWC” or the “Company”) today announced shareholder approval of all resolutions proposed at the 2026 Annual General Meeting of Shareholders (“AGM”) held on September 11, 2026.

“We would like to thank our shareholders for their participation in this year’s Annual General Meeting in person or via telephone conference and for their continued support of the Company,” said Mr. Yuan, APWC’s Chief Executive Officer (“CEO”).

Key Takeaways from the 2026 AGM: APWC’s management reviewed the 2026 Investor Presentation, providing an operational and financial update, highlighting the Company’s first-half 2026 performance, Asia-Pacific investment plans, structural optimization initiatives, and corporate strategies. 

1. First Half 2026 Financial Performance

  • Revenue Growth: H1 2026 revenue increased 17.6% year-over-year to US$267.5 million.
  • Margin Expansion: EBITDA margin improved to 4.56% from 1.66% in the prior-year period.
  • Strong Liquidity: Cash balances increased to US$64.6 million following the successful rights offering completed in Q1 2026.

2. Power Infrastructure Opportunity

  • APWC highlighted its expanding role in regional power and energy infrastructure solutions.
  • Approximately SGD 1 billion in power infrastructure projects in Singapore, expected to be executed over the next four years.
  • Developing the Singapore platform into a regional hub capable of supporting energy storage, AI data center and infrastructure solutions, as well as supply chain management center.

3. Growth Beyond Traditional Wire & Cable

APWC continues to expand downstream into higher value-added business segments, aimed to enhance long-term margin profits and diversify revenue streams. Key growth areas include:

  • Energy storage and power infrastructure solutions.
  • Engineering, Procurement, and Construction (EPC) and Operation & Maintenance (O&M) services.
  • On-train communication systems.
  • Public transportation infrastructure projects.

4. North America Expansion

  • APWC is actively evaluating investment opportunities in and around the State of Texas.
  • Opportunities being explored include association with the TEEMA Industry Park and Taiwan Tower initiatives as potential market-entry platforms.
  • Discussions with partners and customers regarding North American market expansion are in progress.

5. Management Commentary

“We believe APWC is entering a new phase of development, building upon our established wire and cable business while expanding into energy infrastructure, communication systems, and international growth opportunities. Our investment strategy remains focused on long-term value creation.“ commented APWC’s CEO.

Available for review on the Company’s website are the H1 2026 financial results and 2026 Investor Presentation. APWC reminds shareholders and investors that corporate news, initiatives, and financial disclosures are published on its website at APWC Website – Investor Relations.

About Asia Pacific Wire & Cable Corporation Limited

Asia Pacific Wire & Cable Corporation Limited is a holding company incorporated in Bermuda with principal executive offices in Taiwan that conducts its business through operating subsidiaries. Through these subsidiaries, the Company is principally engaged in the manufacture and distribution of enameled wire, power cable, and telecommunications products in Thailand, Singapore, Australia, the People’s Republic of China, Hong Kong and certain other markets in the Asia Pacific region. The Company also engages in the distribution of various wire and cable products manufactured by its controlling shareholder, Pacific Electric Wire & Cable Co., Ltd., and certain third parties. The Company also provides project engineering services in the supply, delivery and installation of power cable. The Company’s major customers include appliance component manufacturers, electrical contracting firms, state owned entities, and wire and cable dealers and factories.

Safe Harbor Statement

This release contains certain “forward-looking statements” relating to the Company, its business, and its subsidiary companies. These forward-looking statements are often identified by the use of forward-looking terminology such as “believes”, “anticipates”, “expects”, “estimates”, “intends”, “plans” or similar expressions. Such forward looking statements involve known and unknown risks and uncertainties that may cause actual results to be materially different from those described herein as believed, anticipated, expected, estimated, intended or planned. Investors should not place undue reliance on these forward-looking statements, which speak only as of the date of this press release. The Company’s actual results could differ materially from those anticipated in these forward-looking statements as a result of a variety of factors, including those discussed in the Company’s reports that are filed with the Securities and Exchange Commission and available on its website (www.sec.gov). All forward-looking statements attributable to the Company, or to persons acting on its behalf, are expressly qualified in their entirety by these factors, other than as required under the securities laws. The Company does not assume a duty to update these forward-looking statements.

Investor Relations Contact:
Pacific Holdings Group
2901 Dallas Parkway, Suite 360
Plano, TX 75093
Attn: Paul Weber
Phone: (469) 797-7191
Email: pweber@pusa.com

Agreement Removes Fixed Expiration Date and Requires 48 Months’ Advance Notice to Terminate, Providing a Minimum Four-Year Term at All Times

ST. PETERSBURG, Fla., Sept. 14, 2026 (GLOBE NEWSWIRE) — American Coastal Insurance Corporation (Nasdaq Ticker: ACIC) (“the Company”, “American Coastal” or “ACIC”), the insurance holding company of American Coastal Insurance Company (“AmCoastal”), announced today that AmCoastal and AmRisc, LLC (“AmRisc”) have restructured their exclusive managing agency agreement, effective July 1, 2026, to remove the agreement’s fixed expiration date. The prior agreement, extended in June 2024, was scheduled to expire on January 1, 2029.

The restructured agreement provides for successive one-year terms that automatically renew, and requires either party to provide 48 months’ advance written notice in order to terminate the agreement for convenience, with the agreement remaining in full force and effect through the notice period. As a result, the agreement has no fixed expiration date and will remain in effect for a minimum of four years from the date any such notice is given.

AmRisc has been AmCoastal’s exclusive distribution and underwriting partner since 2007. AmRisc sources and underwrites the Florida commercial-residential portfolio, and has been profitable in every year since inception. AmRisc is also the Company’s partner in excess and surplus lines. The quota share supporting AmRisc’s nationwide E&S commercial property book added premium to our growing excess and surplus portfolio. Removing the fixed expiration date secures the distribution source behind the Company’s core Florida franchise and the durability of the broader AmRisc relationship.

“AmRisc has been our exclusive distribution and underwriting partner since 2007, and this agreement puts that partnership on a permanent footing,” said Brad Martz, President & CEO. “By removing the fixed expiration date and requiring four years’ notice to terminate, we have given shareholders long-term visibility into the franchise that has produced an underwriting profit every year since inception, and a strong foundation under our most important distribution relationship.”

About American Coastal Insurance Corporation:
American Coastal Insurance Corporation (amcoastal.com) is the holding company of the insurance carrier, American Coastal Insurance Company, which was founded in 2007 for the purpose of insuring Condominium and Homeowner Association properties, Apartments and Assisted Living Facilities in the state of Florida. American Coastal Insurance Company has an exclusive partnership for distribution of Condominium Association properties in the state of Florida with AmRisc Group (amriscgroup.com), one of the largest Managing General Agents in the country specializing in hurricane-exposed properties. American Coastal Insurance Company has earned an “A”, (“Exceptional”) Financial Stability Rating from Demotech and maintains an “A” insurance financial strength rating with a Stable outlook from KBRA. ACIC maintains a “BBB” issuer rating with a Stable outlook from KBRA.

Contact Information:
Alexander Baty
Vice President, Finance & Investor Relations, American Coastal Insurance Corporation
investorrelations@amcoastal.com
(727) 425-8076

Glen Akselrod
President & Founder, Bristol Investor Relations
ga@bristolir.com
(905) 326-1888

  • Company receives third Breakthrough Therapy Designation for RASONQUE and fifth across its portfolio of RAS(ON) inhibitors, further highlighting its differentiated strategy for developing innovative medicines for patients with RAS-addicted cancers

REDWOOD CITY, Calif., Sept. 14, 2026 (GLOBE NEWSWIRE) — Revolution Medicines, Inc. (Nasdaq: RVMD), a global, commercial-stage oncology company dedicated to discovering, developing and delivering innovative medicines for patients with RAS-addicted cancers, today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation to RASONQUE (daraxonrasib), the company’s RAS(ON) multi-selective inhibitor, for treatment-naïve metastatic pancreatic adenocarcinoma (PDAC) in combination with gemcitabine and nab-paclitaxel (GnP), a multiagent chemotherapy regimen widely used in treating patients with PDAC. RASONQUE was recently approved by the U.S. FDA for the treatment of adult patients with metastatic PDAC who have received at least one prior systemic therapy or who are not candidates for multiagent systemic therapy.

The Breakthrough Therapy Designation is based on data from patients with treatment-naïve RAS mutant metastatic PDAC who received RASONQUE in combination with GnP in the open-label, multicenter Phase 1/2 RMC-GI-102 trial. In this cohort, RASONQUE in combination with GnP showed encouraging preliminary antitumor activity and a manageable safety profile that was consistent with the known safety profiles previously observed for both RASONQUE and GnP. These data informed the design of RASolute 303, the ongoing global Phase 3 trial evaluating RASONQUE as monotherapy and in combination with GnP versus GnP alone in patients with previously untreated metastatic PDAC, independent of tumor RAS genotype. The use of RASONQUE in combination with chemotherapy for treatment-naïve metastatic PDAC remains investigational with safety and efficacy not yet established.

“This Breakthrough Therapy Designation underscores the significant unmet need among patients with previously untreated metastatic pancreatic adenocarcinoma and recognizes the importance of advancing new treatment options earlier in their treatment journey,” said Alan Sandler, M.D., chief development officer of Revolution Medicines. “RASONQUE monotherapy demonstrated compelling clinical benefit in the RASolute 302 trial, leading to FDA approval for patients with previously treated metastatic pancreatic adenocarcinoma or those who are not candidates for multiagent systemic therapy. Data from the RMC-GI-102 study have now shown the therapeutic potential of RASONQUE in combination with GnP, a commonly used multiagent systemic therapy, in treatment-naïve patients. Together with our other ongoing studies, these findings reflect our deep commitment to advancing a broad RAS(ON) approach for patients with some of the most difficult-to-treat cancers.”

Breakthrough Therapy Designation is intended to expedite the development and review of potential new medicines designed to treat serious conditions and address significant unmet medical needs. Pursuant to FDA guidelines, the medicine needs to have shown preliminary clinical evidence that demonstrates substantial improvement on a clinically significant endpoint over available medicines.

About Pancreatic Adenocarcinoma (PDAC)
Pancreatic adenocarcinoma, or PDAC, is the most common form of pancreatic cancer and among the most challenging malignancies. Approximately 55,000 people are diagnosed with PDAC in the U.S. each year, and more than 50,000 die from the disease with current standard of care.1,2 Because early-stage pancreatic cancer often causes few or no symptoms, approximately 80% of patients are diagnosed after the disease has spread, when treatment options are more limited. For patients with metastatic PDAC, the five-year relative survival rate is approximately 3% in the U.S.3.4

About RASONQUETM (daraxonrasib)
RASONQUE (daraxonrasib) is an oral, RAS(ON) multi-selective, noncovalent, tri-complex inhibitor (TCI), approved by the U.S. FDA for the treatment of adult patients with metastatic pancreatic adenocarcinoma (PDAC) who have received at least one prior systemic therapy or who are not candidates for multiagent systemic therapy.5 RASONQUE is being investigated through a global Phase 3 registrational program in patients with PDAC and metastatic RAS mutant non-small cell lung cancer (NSCLC). Outside the U.S., RASONQUE is an investigational agent that has not been approved by any regulatory authority.

U.S. FDA APPROVED INDICATION
RASONQUE is indicated for the treatment of adult patients with metastatic pancreatic adenocarcinoma who have received at least one prior systemic therapy or who are not candidates for multiagent systemic therapy.

IMPORTANT SAFETY INFORMATION FOR U.S. APPROVED INDICATION
RASONQUE is associated with the following Warnings and Precautions: Dermatologic and Soft Tissue Toxicity, Stomatitis and Oral Disorders, Diarrhea, Gastrointestinal Perforation, Interstitial Lung Disease (ILD)/Pneumonitis, and Embryo-Fetal Toxicity.

WARNINGS AND PRECAUTIONS

Dermatologic and Soft Tissue Toxicity
RASONQUE can cause dermatologic toxicity, which may be severe. Clinical manifestations included, but were not limited to, rash, pruritus, paronychia, dry skin, and skin fissures. In clinical trials of patients with pancreatic adenocarcinoma, dermatologic toxicity occurred in 86% of patients treated with RASONQUE, of which 10% were Grade 3.

Monitor patients who develop dermatologic or soft tissue toxicities while receiving RASONQUE. Initiate prophylactic measures (e.g., topical corticosteroids, emollient creams, sunscreen, oral antibiotics) prior to the first dose of RASONQUE to reduce the risk of moderate to severe dermatologic reactions. Advise patients to limit sun exposure while taking RASONQUE. Initiate supportive measures (e.g., oral corticosteroids) as clinically indicated, and consider dermatologic consultation. Withhold, reduce the dose, or permanently discontinue RASONQUE based on severity.

Stomatitis and Oral Disorders
RASONQUE can cause stomatitis, including mouth ulcers and oral mucositis. In clinical trials of patients with pancreatic adenocarcinoma, stomatitis occurred in 57% of patients, of which 9% were Grade 3.

Monitor patients for signs and symptoms of stomatitis while receiving RASONQUE. Initiate a steroid-containing mouthwash for treatment of stomatitis and administer other topical treatments (e.g., chlorhexidine mouthwash, 2% lidocaine viscous) as clinically indicated. Withhold, reduce the dose, or permanently discontinue RASONQUE based on severity.

Diarrhea
RASONQUE can cause diarrhea. In clinical trials of patients with pancreatic adenocarcinoma, diarrhea occurred in 63% of patients, of which 6% were Grade 3.
If diarrhea occurs, administer antidiarrheal treatment as clinically indicated. Withhold, reduce the dose, or permanently discontinue RASONQUE based on severity.

Gastrointestinal Perforation
RASONQUE can cause gastrointestinal perforation. In clinical trials of patients with pancreatic adenocarcinoma, gastrointestinal perforation occurred in 0.9% of patients treated with RASONQUE, of which 0.5% were Grade 3, one event was Grade 4, and one event was fatal.

Monitor patients for gastrointestinal perforation. Withhold RASONQUE if gastrointestinal perforation is suspected. Reduce the dose or permanently discontinue RASONQUE if no other potential causes of gastrointestinal perforation are identified.

Interstitial Lung Disease (ILD)/Pneumonitis
RASONQUE can cause interstitial lung disease or pneumonitis. In clinical trials of patients with pancreatic adenocarcinoma, ILD/pneumonitis occurred in 2.4% of patients treated with RASONQUE, of which 0.9% were Grade 3, and one event was fatal.

Monitor patients for new or worsening pulmonary symptoms. Withhold RASONQUE if ILD/pneumonitis is suspected. Reduce the dose or permanently discontinue RASONQUE if no other potential causes of ILD/pneumonitis are identified.

Embryo-Fetal Toxicity
Based on findings in animals, RASONQUE can cause fetal harm when administered to a pregnant woman. Advise females of reproductive potential to use effective contraception during treatment with RASONQUE and for 1 week after the last dose. Advise males with female partners of reproductive potential to use effective contraception during treatment with RASONQUE and for 1 week after the last dose.

ADVERSE REACTIONS
Serious adverse reactions occurred in 30% of patients treated with RASONQUE. Serious adverse reactions occurring in ≥ 2% of patients treated with RASONQUE were diarrhea (3.7%), pyrexia (3.3%), sepsis (2.9%), fatigue (2.1%), and hemorrhage (2.1%).

Adverse reactions leading to permanent discontinuation of RASONQUE occurred in 2.9% of patients, including two patients who discontinued due to rash (0.8%).

The most common (≥ 20%) adverse reactions in patients treated with RASONQUE were rash, diarrhea, stomatitis, nausea, fatigue, vomiting, abdominal pain, edema, decreased appetite, and hemorrhage.

DRUG INTERACTIONS

  • Strong CYP3A Inhibitors with P-gp Inhibition: Avoid concomitant use.
  • Strong CYP3A Inhibitors without P-gp Inhibition: Reduce RASONQUE dosage.
  • Moderate CYP3A Inhibitors with or without P-gp Inhibition: Reduce RASONQUE dosage.
  • P-gp Inhibitors: Reduce RASONQUE dosage.
  • Cyclosporine A: Avoid concomitant use.
  • Strong CYP3A Inducers: Avoid concomitant use. Increase RASONQUE dosage if concomitant use cannot be avoided.
  • Moderate CYP3A Inducers: Increase RASONQUE dosage.
  • P-gp Substrates: Take at least 4 hours apart from RASONQUE.

PROPHYLACTIC MEASURES
When initiating RASONQUE and throughout treatment, prophylactic and concomitant medications are recommended to reduce the risk of dermatologic reactions:

  • administer a topical corticosteroid (applied to the face and chest) and emollient creams;
  • advise patients to limit sun exposure and use broad-spectrum sunscreen (SPF 30 or higher); and
  • consider prophylactic oral antibiotics (e.g., doxycycline or minocycline).

Please see U.S. Full Prescribing Information for RASONQUE

About Revolution Medicines, Inc.
Revolution Medicines is a global, commercial-stage oncology company dedicated to discovering, developing and delivering innovative medicines for patients with RAS-addicted cancers. Leveraging its differentiated RAS(ON) tri-complex inhibitor platform, the company is advancing a broad, integrated portfolio of oral RAS(ON) inhibitors designed to directly target the active, cancer-driving state of RAS. Founded on rigorous scientific inquiry and a willingness to challenge long-held assumptions, Revolution Medicines is committed to changing the trajectory of disease for patients with RAS-addicted cancers worldwide. For more information, visit www.revmed.com and follow Revolution Medicines on LinkedIn, X (Twitter) and Instagram.

Forward-Looking Statements 

This press release contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Any statements in this press release that are not historical facts may be considered “forward-looking statements,” including without limitation statements regarding the broad potential of RAS(ON) inhibition; treatment practices; the company’s regulatory interactions and the potential for Breakthrough Therapy Designation to expedite the development and review of new medicines; reactions to RASONQUE; and progression of clinical studies and findings from these studies, including the tolerability, safety, and potential efficacy of the company’s candidates being studied.

Forward-looking statements are typically, but not always, identified by the use of words such as “aims,” “anticipate,” “believe,” “estimate,” “expect,” “plan,” “potential,” “project,” “up to,” “will” and other similar terminology indicating future results. Such forward-looking statements are subject to substantial risks and uncertainties that could cause the company’s development programs, future results, performance, or achievements to differ materially from those anticipated in the forward-looking statements. Such risks and uncertainties include without limitation risks and uncertainties inherent in the drug development process, including the company’s programs’ development stages, the process of designing and conducting preclinical and clinical trials, the regulatory approval processes, the timing of regulatory filings, the challenges associated with manufacturing drug products, the company’s ability to successfully establish, protect and defend its intellectual property, other matters that could affect the sufficiency of the company’s capital resources to fund operations, reliance on third parties for manufacturing and development efforts, changes in the competitive landscape, and the effects on the company’s business of global events, such as international conflicts or global pandemics. For a further description of the risks and uncertainties that could cause actual results to differ from those anticipated in these forward-looking statements, as well as risks relating to the business of Revolution Medicines in general, see Revolution Medicines’ Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission (the “SEC”) on August 5, 2026, and its future periodic reports to be filed with the SEC. Except as required by law, Revolution Medicines undertakes no obligation to update any forward-looking statements to reflect new information, events, or circumstances, or to reflect the occurrence of unanticipated events.

Revolution Medicines Media & Investor Contacts 

Media
media@revmed.com  

Investors
investors@revmed.com 

References

1 Oracle CancerMPact Patient Metrics, Stage IV newly incident + recurrent from earlier stages. Accessed July 2026.
2 Siegel RL, Giaquinto AN, Jemal A. Cancer statistics, 2024. CA Cancer J Clin. 2024;74(1):12-49. doi:10.3322/caac.21820
3 Halbrook CJ, Lyssiotis CA, Pasca di Magliano M, Maitra A. Pancreatic cancer: Advances and challenges. Cell. 2023;186(8):1729-1754. doi:10.1016/j.cell.2023.02.014
4 American Cancer Society. Survival Rates for Pancreatic Cancer. Available at: https://www.cancer.org/cancer/types/pancreatic-cancer/detection-diagnosis-staging/survival-rates.html. Accessed September 2026.
5 RASONQUE (daraxonrasib) Prescribing Information. Redwood City, CA: Revolution Medicines, Inc.; August 2026.

DALLAS, Sept. 14, 2026 (GLOBE NEWSWIRE) — Dave & Buster’s Entertainment, Inc. (NASDAQ: PLAY) (“Dave & Buster’s” or “the Company”), an owner, operator, and franchisor of entertainment and dining venues, today announced financial results for its second quarter of fiscal 2026 ended August 4, 2026.

Second Quarter 2026 Financial Summary

  • Revenue of $544.1 million decreased 2.4% from the second quarter of fiscal 2025.
  • Comparable store sales decreased 2.9% compared to the same calendar period in fiscal 2025.
  • Net loss totaled $12.5 million, or a $0.36 net loss per diluted share, compared to net income of $11.4 million, or $0.32 net income per diluted share in the second quarter of fiscal 2025. Adjusted net loss1 totaled $9.5 million, or a $0.27 Adjusted net loss per diluted share, compared to Adjusted net income1 of $14.2 million, or $0.40 Adjusted net income per diluted share in the second quarter of fiscal 2025.
  • Adjusted EBITDA1 was $98.9 million compared to $129.8 million in the second quarter of fiscal 2025.
  • Adjusted free cash flow1 was positive $19.5 million for the six months ended August 4, 2026 compared to negative $36.5 million through the end of the six months ended August 5, 2025.

Additional Events and Commentary

  • The Company opened six new domestic stores in the second quarter.
  • The Company expects to complete two additional Dave & Buster’s store remodels during the remainder of fiscal 2026, bringing the total number of remodels completed in fiscal 2026 to eight.
  • The Company has six international franchise stores and expects to open at least one additional international franchise store during the remainder of fiscal 2026.

“We are energized by the obvious, actionable, and enormous opportunities ahead for Dave & Buster’s and Main Event,” said Darin Harper, Chief Executive Officer. “Our Back-to-Basics strategy is gaining momentum with enhanced executional urgency. We are experiencing ongoing growth in food and beverage sales as well as in special events sales. The same store sales of our remodels continue to outperform the system. Further, we improved overall same store sales in July, and saw continued improvement in overall same store sales during the third quarter to date. We are laser focused on returning to same-store sales and EBITDA growth, sharpening our margin management with cost saving initiatives, generating significant free cash flow, and delivering meaningful shareholder value. I have tremendous confidence in the direction of our business and am excited about what we will accomplish together as we shape the future of our company.”

______________________
1 Adjusted EBITDA, Adjusted net income (loss) and Adjusted free cash flow are non-GAAP financial measures. Please see the discussion under Non-GAAP Measures and the reconciliations at the end of this release for additional information concerning these and other non-GAAP financial measures.

Cash Flow and Liquidity

The Company generated $19.5 million in Adjusted free cash flow for the six months ended August 4, 2026, ending the quarter with $492.1 million of available liquidity1.

Quarterly Report on Form 10-Q Available

The Company’s Quarterly Report on Form 10-Q, which will be available at www.sec.gov and on the Company’s investor relations website, contains a thorough review of its financial results for the second quarter ended August 4, 2026.

Investor Conference Call and Webcast

Management will host a conference call to discuss these results on Monday, September 14, 2026 at 4:00 p.m. Central Time (5:00 p.m. Eastern Time). Both the live and archived webcasts of the conference call will be available at ir.daveandbusters.com. Participants in the U.S. can access the conference call by dialing toll-free (888) 596-4144, and international participants can access by dialing +1 (646) 968-2525. The conference ID is 3278311. A replay will be available after the call beginning at 6:00 p.m. Central Time (7:00 p.m. Eastern Time) and can be accessed by dialing toll-free (800) 770-2030 or by the toll number +1 (609) 800-9909. The replay conference ID is also 3278311.

About Dave & Buster’s Entertainment, Inc.

Founded in 1982 and headquartered in Coppell, Texas, Dave & Buster’s Entertainment, Inc. is the owner and operator of 250 stores in North America that offer premier entertainment and dining experiences to guests through two distinct brands: Dave & Buster’s and Main Event. The Company has 184 Dave & Buster’s branded stores in 43 states, Puerto Rico, and Canada, and offers guests the opportunity to “Eat, Drink, Play, and Watch” all in one location. Each store offers a full menu of entrées and appetizers, a complete selection of alcoholic and non-alcoholic beverages, and an extensive assortment of entertainment attractions centered around playing games and watching live sports and other televised events. The Company also operates 66 Main Event branded stores in 24 states across the country, and offers state-of-the-art bowling, laser tag, hundreds of arcade games and virtual reality, making it the perfect place for families to connect and make memories. Internationally, the Company is in early-stage growth as a franchisor of its brands with six Dave & Buster’s franchise stores currently open. For more information about each brand, visit daveandbusters.com and mainevent.com.

Forward-Looking Statements

The Company cautions that this release contains statements that are, or may be deemed to be, “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements can be identified by the use of forward-looking terminology, including the terms “believes,” “estimates,” “anticipates,” “expects,” “intends,” “may,” “will” or “should” or, in each case, their negative or other variations or comparable terminology. Forward-looking statements are neither historical facts nor assurances of future performance, and are based only on our current beliefs, expectations and assumptions regarding the future of our business, future plans and strategies, projections, anticipated events and trends, the economy and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of our control. These forward-looking statements include all matters that are not historical facts, including statements regarding our intentions, beliefs or current expectations concerning, among other things: our results of operations; financial condition; liquidity; prospects; growth; strategies; the industry in which we operate; expansion and opening of new locations; and opportunities and risks affecting our business, industry and financial results, including macroeconomic factors. These forward-looking statements involve risks and uncertainties, including: our ability to successfully design and execute our business strategy; our effectiveness at integrating and operating our past or future acquisitions; the effects of new or improved technologies or changes in consumer behavior; the potential for unfavorable publicity; our ability to obtain and renew leases on favorable terms or at all; our substantial indebtedness and covenants in our debt agreements restricting our ability to implement our business plan; our success in opening and operating new stores profitably and optimizing existing stores; risks related to our information systems and potential cybersecurity breaches or other privacy or data incidents; the cost and availability of certain commodities; our procurement of new games and entertainment offerings and our ability to obtain related licensing rights; the extensive laws and regulations in which we must comply with; and other risks identified in “Risk Factors” in our reports filed with the Securities and Exchange Commission. Accordingly, actual results may differ materially from the forward-looking statements, and the Company therefore cautions you against relying on such forward-looking statements. The Company intends these forward-looking statements to speak only as of the time of this release and does not undertake to update or revise them as more appropriate information becomes available, except as required by law.

___________________
1 Available liquidity is defined as cash and cash equivalents plus availability under the Company’s $650.0 million revolving credit facility.

Non-GAAP Measures

To supplement its consolidated financial statements, which are prepared and presented in accordance with accounting principles generally accepted in the United States of America (“GAAP”), the Company uses the following non-GAAP financial measures: Adjusted EBITDA, Credit Adjusted EBITDA (calculated in accordance with the Company’s Credit Facility), Net Total Leverage Ratio (calculated in accordance with the Company’s Credit Facility), Store operating income before depreciation and amortization, Adjusted net income (loss), Adjusted net income (loss) per share – diluted, and Adjusted free cash flow, reconciliations or numerical inputs of which can be found on the following pages (collectively the “non-GAAP financial measures”). The presentation of this financial information is not intended to be considered in isolation or as a substitute for, or superior to, the financial information prepared and presented in accordance with GAAP. The Company uses these non-GAAP financial measures for financial and operational decision making and as a means to evaluate period-to-period comparisons. The Company believes that they provide useful information about operating results, enhance the overall understanding of our operating performance and future prospects, and allow for greater transparency with respect to key metrics used by management in its financial and operational decision making. The non-GAAP measures used by the Company in this press release may be different from the measures used by other companies or calculated differently than similar measures used by other companies.

For Investor Relations Inquiries:

Investor@daveandbusters.com

 
DAVE & BUSTER’S ENTERTAINMENT, INC.
Consolidated Statements of Operations
(unaudited, in millions, except per share amounts)
         
    Three Months Ended   Six Months Ended
    August 4, 2026   August 5, 2025   August 4, 2026   August 5, 2025
Entertainment revenues   $ 332.6     61.1 %   $ 364.5   65.4 %   $ 677.7     61.4 %   $ 731.1   65.0 %
Food and beverage revenues     211.5     38.9 %     192.9   34.6 %     425.6     38.6 %     393.9   35.0 %
Total revenues     544.1     100.0 %     557.4   100.0 %     1,103.3     100.0 %     1,125.0   100.0 %
Cost of entertainment     30.7     9.2 %     29.2   8.0 %     58.1     8.6 %     59.8   8.2 %
Cost of food and beverage     52.5     24.8 %     47.2   24.5 %     104.9     24.6 %     98.8   25.1 %
Total cost of products     83.2     15.3 %     76.4   13.7 %     163.0     14.8 %     158.6   14.1 %
Operating payroll and benefits     140.2     25.8 %     138.7   24.9 %     280.3     25.4 %     273.7   24.3 %
Other store operating expenses     192.9     35.5 %     186.9   33.5 %     379.6     34.4 %     375.3   33.4 %
General and administrative expenses     27.1     5.0 %     32.0   5.7 %     54.6     4.9 %     56.3   5.0 %
Depreciation and amortization expenses     73.7     13.5 %     65.2   11.7 %     144.6     13.1 %     128.4   11.4 %
Pre-opening costs     6.7     1.2 %     4.1   0.7 %     12.1     1.1 %     10.1   0.9 %
Other charges and gains     0.9     0.2 %     1.1   0.2 %     2.8     0.3 %     6.4   0.6 %
Total operating costs     524.7     96.4 %     504.4   90.5 %     1,037.0     94.0 %     1,008.8   89.7 %
Operating income     19.4     3.6 %     53.0   9.5 %     66.3     6.0 %     116.2   10.3 %
Interest expense, net     38.0     7.0 %     38.7   6.9 %     74.9     6.8 %     75.5   6.7 %
Income (loss) before income taxes     (18.6 )   (3.4 )%     14.3   2.6 %     (8.6 )   (0.8 )%     40.7   3.6 %
Provision for (benefit from) income taxes     (6.1 )   (1.1 )%     2.9   0.5 %     (1.8 )   (0.2 )%     7.6   0.7 %
Net income (loss)   $ (12.5 )   (2.3 )%   $ 11.4   2.0 %   $ (6.8 )   (0.6 )%   $ 33.1   2.9 %
                                 
Net income (loss) per share:                                
Basic   $ (0.36 )       $ 0.33       $ (0.20 )       $ 0.96    
Diluted   $ (0.36 )       $ 0.32       $ (0.20 )       $ 0.94    
Weighted average shares used in per share calculations:                                
Basic shares     34.81           34.52         34.78           34.56    
Diluted shares     34.81           35.14         34.78           35.08    
                                 
Other information:                                
Company-owned stores at end of period     250           237         250           237    
Store operating weeks in the period     3,204           3,066         6,364           6,081    
Total revenue per store operating weeks in the period (in thousands)   $ 170         $ 182       $ 173         $ 185    
Total revenue per square foot per store operating weeks in the period (in dollars)   $ 4.15         $ 4.43       $ 4.23         $ 4.49    

(1)   All percentages are expressed as a percentage of total revenues for the respective period presented, except cost of entertainment, which is expressed as a percentage of entertainment revenues, and cost of food and beverage, which is expressed as a percentage of food and beverage revenues.
     


 
DAVE & BUSTER’S ENTERTAINMENT, INC.
Other Financial Data
(unaudited, in millions)
 
Condensed Consolidated Balance Sheets:
       
  August 4, 2026
  February 3, 2026
ASSETS          
Cash and cash equivalents $ 16.0     $ 16.6  
Other current assets   111.8       107.5  
Total current assets   127.8       124.1  
Property and equipment, net   1,739.9       1,719.0  
Operating lease right of use assets   1,283.1       1,303.2  
Intangible and other assets, net   970.1       970.3  
Total assets $ 4,120.9     $ 4,116.6  
           
LIABILITIES AND STOCKHOLDERS’ EQUITY          
Total current liabilities $ 430.7     $ 434.6  
Deferred income taxes   66.6       68.6  
Operating lease liabilities   1,539.4       1,562.6  
Other long-term liabilities   495.8       444.6  
Long-term debt, net   1,500.5       1,515.0  
Stockholders’ equity   87.9       91.2  
Total liabilities and stockholders’ equity $ 4,120.9     $ 4,116.6  

Summary Cash Flow Information:
         
    Three Months Ended   Six Months Ended
    August 4, 2026   August 5, 2025   August 4, 2026   August 5, 2025
Net cash provided by (used in):                
Operating activities:   $ 46.8     $ 34.0     $ 160.6     $ 129.8  
Investing activities:     (84.7 )     (84.7 )     (190.0 )     (239.3 )
Financing activities:     34.3       50.8       28.8       114.6  
Increase (decrease) in cash and cash equivalents   $ (3.6 )   $ 0.1     $ (0.6 )   $ 5.1  
                                 


 
DAVE & BUSTER’S ENTERTAINMENT, INC.
Non-GAAP Measures
(unaudited, in millions)
 

Adjusted EBITDA:

Adjusted EBITDA represents net income (loss), plus interest expense, net, loss on debt refinancing, provision for (benefit from) income taxes, depreciation and amortization expense, (gain) loss on property and equipment transactions, impairment of long-lived assets, share-based compensation, currency transaction (gains) losses, transaction and integration costs, system implementation costs and certain other costs, as calculated below. Adjusted EBITDA is a non-GAAP financial measure commonly used in our industry and should not be construed as an alternative to net income as an indicator of operating performance or as an alternative to cash flow provided by operating activities as a measure of liquidity (as determined in accordance with GAAP). Adjusted EBITDA may not be comparable to similarly titled measures reported by other companies. Adjusted EBITDA is presented because we believe that it provides useful information to investors and analysts regarding our operating performance. By reporting Adjusted EBITDA, we provide a basis for comparison of our business operations between current, past and future periods by excluding items that we do not believe are indicative of our core operating performance. A reconciliation of net income (loss) to Adjusted EBITDA is provided below for the periods presented:

  Three Months Ended   Six Months Ended
  August 4, 2026(1)   August 5, 2025(1)   August 4, 2026(1)   August 5, 2025(1)
Net income (loss) $ (12.5 )   (2.3 )%   $ 11.4     2.0 %   $ (6.8 )   (0.6 )%   $ 33.1     2.9 %
Add back:                                  
Interest expense, net   38.0           38.7           74.9           75.5      
Provision for (benefit from) income taxes   (6.1 )         2.9           (1.8 )         7.6      
Depreciation and amortization expense   73.7           65.2           144.6           128.4      
Share-based compensation(2)   0.9           7.9           3.4           10.9      
Transaction and integration costs(3)   —           0.2           —           0.4      
System implementation costs(4)   —           0.9           —           2.5      
Loss on property and equipment transactions(5)   0.9           0.2           2.8           3.9      
Other items, net(6)   4.0           2.4           4.9           3.5      
Adjusted EBITDA, a non-GAAP measure(1) $ 98.9     18.2 %   $ 129.8     23.3 %   $ 222.0     20.1 %   $ 265.8     23.6 %

(1)   All percentages are expressed as a percentage of total revenues for the respective period presented.
(2)   Non-cash share-based compensation expense, net of forfeitures, recorded in General and administrative expenses on the Consolidated Statements of Comprehensive Income (Loss).
(3)   Transaction and integration costs related to the acquisition and integration of Main Event recorded in General and administrative expenses on the Consolidated Statements of Comprehensive Income (Loss)
(4)   System implementation costs represent expenses incurred related to the development of new enterprise resource planning, human capital management and inventory software for our stores and store support teams. These charges are recorded in Other charges and gains on the Consolidated Statements of Comprehensive Income (Loss).
(5)   Loss on property and equipment transactions primarily represents the net book value of assets retired and certain costs associated with the retirement of those assets.
(6)   The amounts for the 2026 periods primarily consisted of severance and restructuring charges, one-time third-party legal consulting fees, a discrete legal settlement outside of the normal course of business, and various individually immaterial adjustments. The amount for the fiscal 2025 periods primarily consisted of discretionary retention incentives, one-time, third-party consulting fees, and severance costs.
     

Store Operating Income Before Depreciation and Amortization:

Store Operating Income Before Depreciation and Amortization, a non-GAAP measure, represents operating income, plus depreciation and amortization expense, general and administrative expenses, pre-opening costs and other gains and charges. We believe that Store Operating Income Before Depreciation and Amortization is another useful measure in evaluating our operating performance because it removes the impact of general and administrative expenses, which are not incurred at the store level, and the costs of opening new stores, which are non-recurring at the store level, and thereby enables the comparability of the operating performance of our stores for the periods presented. We also believe that Store Operating Income Before Depreciation and Amortization is a useful measure in evaluating our operating performance within the entertainment and dining industry because it permits the evaluation of store-level productivity, efficiency, and performance, and we use Store Operating Income Before Depreciation and Amortization as a means of evaluating store financial performance compared with our competitors. However, because this measure excludes significant items such as general and administrative expenses, pre-opening costs and other gains and charges, as well as our interest expense, net, loss on debt extinguishment/refinance and depreciation and amortization expense, which are important in evaluating our consolidated financial performance from period to period, the value of this measure is limited as a measure of our consolidated financial performance. A reconciliation of operating income to Store Operating Income Before Depreciation and Amortization is provided below for the periods presented:

  Three Months Ended   Six Months Ended
  August 4, 2026(1)   August 5, 2025(1)   August 4, 2026(1)   August 5, 2025(1)
Operating income $ 19.4     3.6 %   $ 53.0     9.5 %   $ 66.3     6.0 %   $ 116.2     10.3 %
Add back:                                      
General and administrative expenses   27.1           32.0           54.6           56.3      
Depreciation and amortization expense   73.7           65.2           144.6           128.4      
Pre-opening costs   6.7           4.1           12.1           10.1      
Other gains and charges   0.9           1.1           2.8           6.4      
Store operating income before depreciation and amortization, a non-GAAP measure $ 127.8     23.5 %   $ 155.4     27.9 %   $ 280.4     25.4 %   $ 317.4     28.2 %

(1)   All percentages are expressed as a percentage of total revenues for the respective period presented.
     

Adjusted free cash flow:

Adjusted free cash flow, a non-GAAP measure, represents Net cash provided by operating activities less capital expenditures, plus payments received from landlords related to sale-leaseback transactions and finance leases. Management believes adjusted free cash flow provides investors with an additional measure of the cash generated by the business after considering routine capital investment requirements. A reconciliation of Net cash provided by operating activities to Adjusted free cash flow is provided below for the periods presented:

    Six Months Ended
    August 4, 2026   August 5, 2025
Net cash provided by operating activities   $ 160.6     $ 129.8  
Less: Capital expenditures     (190.0 )     (243.8 )
Add: Incentives from landlords – finance leases     —       4.5  
Add: Proceeds from sale-leaseback transactions     48.9       73.0  
Adjusted free cash flow, a non-GAAP measure   $ 19.5     $ (36.5 )
                 

Credit Adjusted EBITDA and Net Total Leverage Ratio:

Credit Adjusted EBITDA, a non-GAAP measure, represents net loss plus certain items as defined at Adjusted EBITDA above, as well as certain other adjustments as defined in our Credit Agreement. These other adjustments include (i) entertainment revenue deferrals, (ii) the cost of new projects, including store pre-opening costs, (iii) business optimization expenses and other restructuring costs, and (iv) other costs and adjustments as permitted by the Credit Agreement. We believe the presentation of Credit Adjusted EBITDA is appropriate as it provides additional information to investors about the calculation of, and compliance with, certain financial covenants in the Credit Agreement. The following table sets forth a reconciliation of Net loss to Credit Adjusted EBITDA for the period shown:

    Trailing Four Quarters Ended
August 4, 2026
Net loss   $ (88.7 )
Add back:    
Interest expense, net     153.4  
Loss on debt refinancing     —  
Provision for income taxes     (28.6 )
Depreciation and amortization expense     295.6  
Share-based compensation(1)     12.1  
Transaction and integration costs(2)     0.3  
System implementation costs(3)     0.9  
Loss on property and equipment transactions and impairments(4)     35.7  
Other items, net(5)     12.1  
Pre-opening costs(6)     21.1  
Credit Facility specific items, net(7)     21.9  
Credit Adjusted EBITDA, a non-GAAP measure   $ 435.8  

(1)   See discussion of share-based compensation at Adjusted EBITDA above.
(2)   See discussion of transaction and integration costs at Adjusted EBITDA above.
(3)   See discussion of system implementation costs at Adjusted EBITDA above.
(4)   Consists of store asset impairments and loss on property and equipment disposals.
(5)   Primarily consists of discretionary retention incentives, severance costs and certain third-party consulting fees. The third-party consulting fees are not part of our ongoing operations and were incurred in association with a change in leadership to execute discrete, project-based strategic initiatives aimed at analyzing and summarizing growth opportunities and cost reductions for the Company. The transformative nature, narrow scope, and limited duration of these incremental consulting fees are not reflective of the ordinary course expenses incurred to operate our business. Third-party consulting fees, discretionary retention incentives and severance costs are included in General and administrative expenses on the Consolidated Statements of Comprehensive Income (Loss).
(6)   Represents costs incurred, primarily consisting of occupancy and payroll related expenses, associated with the opening of new stores. These costs are considered a “cost of new projects” as defined in our Credit Facility.
(7)   Represents other adjustments allowed under our Credit Agreement in the determination of Net Total Leverage Ratio including (i) amortization of software costs, (ii) executive search fees, (iii) public company costs, (iv) estimated impact of remodels to financial performance, (v) the pro forma impact of certain leases that were reclassified as finance leases during fiscal 2025 and (vi) the pro forma impact of certain implemented cost saving initiatives.
     

The following table provides a calculation of Net Total Leverage Ratio, as defined in the Credit Agreement, for the period shown:

  As of, and for the Trailing Four Quarters Ended
August 4, 2026
Credit Adjusted EBITDA (a) $ 435.8  
Total debt(1)   1,540.4  
Less: Cash and cash equivalents   (16.0 )
Add: Outstanding letters of credit   18.9  
Net debt (b) $ 1,543.3  
Net Total Leverage Ratio (b / a) 3.5 x

(1)   Amount represents the sum of the carrying amount of debt outstanding and finance lease liabilities.
     

Adjusted Net Income (Loss) and Adjusted Net Income (Loss) Per Share – Diluted:

Adjusted net income (loss), a non-GAAP measure, represents net income (loss) before special items, as calculated below, and Adjusted net income (loss) per share – diluted, a non-GAAP measure, represents Adjusted net income (loss) on a fully diluted, per share basis. We believe excluding these special items from net income (loss) provides investors with a clearer perspective of our ongoing operating performance and a more relevant comparison to prior period results. The following table presents a reconciliation of net income (loss) to Adjusted net income (loss) and presents Adjusted net income (loss) per diluted share, for the periods shown:

  Three Months Ended   Six Months Ended
  August 4, 2026   August 5, 2025   August 4, 2026   August 5, 2025
  $   Per Diluted Share   $   Per Diluted Share   $   Per Diluted Share   $   Per Diluted Share
Net income (loss) and net income (loss) per diluted share $ (12.5 )   $ (0.36 )   $ 11.4     $ 0.32     $ (6.8 )   $ (0.20 )   $ 33.1     $ 0.94  
Adjustments:                              
Transaction and integration costs(1)   —       —       0.2       0.01       —       —       0.4       0.01  
System implementation costs(2)   —       —       0.9       0.03       —       —       2.5       0.07  
Loss on property and
equipment transactions(3)
  —       —       0.2       0.01       0.0       0.00       3.9       0.11  
Other items, net(4)   4.0       0.11       2.4       0.07       4.9       0.14       3.5       0.10  
Tax impact of items above, net(5)   (1.0 )     (0.03 )     (0.9 )     (0.03 )     (1.3 )     (0.03 )     (2.7 )     (0.08 )
Adjusted net income (loss) and Adjusted net income (loss) per share – diluted, non-GAAP measures $ (9.5 )   $ (0.27 )   $ 14.2     $ 0.40     $ (3.2 )   $ (0.09 )   $ 40.7     $ 1.16  

(1)   See discussion of transaction and integration costs at Adjusted EBITDA above.
(2)   See discussion of system implementation costs at Adjusted EBITDA above.
(3)   Loss on property and equipment transactions primarily represents the net book value of assets retired and certain costs associated with the retirement of those assets.
(4)   See discussion of other items, net at Adjusted EBITDA above.
(5)   The income tax effect related to special items is based on the blended jurisdictional statutory tax rates for the applicable period.
     

SHAKOPEE, Minn., Sept. 14, 2026 (GLOBE NEWSWIRE) — Canterbury Park Holding Corporation (“Canterbury” or the “Company”) (NASDAQ: CPHC), today announced that the Company’s Board of Directors, pursuant to its dividend policy, approved a quarterly cash dividend of $0.07 per share that will be paid on October 14, 2026 to stockholders of record on September 30, 2026. At this quarterly rate, the annual dividend is equivalent to $0.28 per common share.

About Canterbury Park

Canterbury Park Holding Corporation (Nasdaq: CPHC) owns and operates Canterbury Park Racetrack and Casino in Shakopee, Minnesota, the only thoroughbred and quarter horse racing facility in the State. The Company generally offers live racing from May to September. The Casino hosts card games 24 hours a day, seven days a week, dealing both poker and table games. The Company also conducts year-round wagering on simulcast horse racing and hosts a variety of other entertainment and special events at its Shakopee facility. The Company is also pursuing a strategy to enhance shareholder value by the ongoing development of approximately 140 acres of underutilized land surrounding the Racetrack that was originally designated for a project known as Canterbury Commons™. The Company is pursuing several mixed-use development opportunities for the remaining underutilized land, directly and through joint ventures. For more information about the Company, please visit www.canterburypark.com.

Cautionary Statement

From time to time, in press releases and in other communications to shareholders or the investing public, Canterbury Park Holding Corporation may make forward-looking statements concerning possible or anticipated future financial performance, business activities or plans based on management’s beliefs and assumptions. These forward looking statements are typically preceded by the words such as “believes,” “expects,” “anticipates,” “intends” or similar expressions. Shareholders and the investing public should understand that these forward-looking statements are subject to risks and uncertainties, including those disclosed in our periodic filings with the Securities and Exchange Commission, which could cause actual performance, activities, future dividends or plans after the date the statements are made to differ significantly from those indicated in the forward-looking statements when made.

Investor Contact:

Randy Dehmer                                                        
Senior Vice President and Chief Financial Officer                        
Canterbury Park Holding Corporation                                
952-233-4828 or investorrelations@canterburypark.com

— Topline Phase 1 data shows generally favorable safety and tolerability profile of AGMB-447 —

— Pharmacokinetic profile confirms efficient lung restriction with low systemic exposure and high exposure of AGMB-447 in the lung, in line with prior results observed in healthy participants —

— Robust target engagement of ALK5 observed with AGMB-447 in IPF patients —

— Clinical Trial Application (CTA) for INSPIRIA Phase 2 study in IPF patients submitted; Company intends to initiate study before year-end —

Antwerp, Belgium, September 14, 2026 – Agomab Therapeutics NV (‘Agomab’), a clinical-stage biopharmaceutical company focused on fibro-inflammation, today announced positive results of the Phase 1 study of AGMB-447 in IPF patients. AGMB-447 is an investigational inhaled lung-restricted small molecule inhibitor of ALK5 (or TGFβR1) intended for the treatment of Idiopathic Pulmonary Fibrosis (IPF).1

The Phase 1 study of AGMB-447 is a three-part, double-blind, randomized, placebo-controlled single ascending dose (SAD; Part A; dose range: 1 mg QD (once daily) to 20 mg QD) and multiple ascending dose (MAD; Part B; dose range: 1 mg QD to 6 mg BID (twice daily)) study in healthy participants and multiple dose study in IPF patients (Part C; dose range: 4.5 mg BID to 6 mg BID). AGMB-447 was administered via nebulization, as a single dose in the SAD, over seven days in Part B and over 14 days in Part C.

A total of 10 IPF patients were included in Part C. In line with the data in healthy participants reported previously, AGMB-447 was observed to have a generally favorable safety and tolerability profile in IPF patients at 4.5 mg BID. While a higher incidence of adverse events was reported at 6 mg BID, no new specific safety signals were identified, and no systemic safety signals were detected at any dose. The most frequently reported adverse events were cough and bronchospasm. Cough episodes were short and mostly limited to the inhalation period. Furthermore, no increase in the severity of disease-related cough was reported at any dose over the 14-day dosing period.

Low systemic but high pulmonary exposure of AGMB-447 was also measured in IPF patients, supporting its lung-restricted pharmacokinetic (PK) profile. In IPF patients, daily doses of 4.5 mg BID achieved average bronchoalveolar lavage (BAL) fluid levels above IC90 for at least 6 hours post-inhalation, and above IC50 for 24 hours, in line with the PK profile observed in healthy participants.

In IPF patients, pSMAD3 reduction in BAL cells of >50% was achieved at the 4.5 mg BID dose, indicating robust target engagement in line with the results observed previously in healthy participants and supporting further clinical development of AGMB-447 for the treatment of IPF.

“We are very pleased with the Phase 1 results of AGMB-447 in patients with IPF announced today. In line with the positive interim data in healthy participants announced earlier this year, the data indicated a generally favorable safety, tolerability and PK profile of AGMB-447 and provided proof-of-mechanism of TGFβ/ALK5 inhibition in the lungs of IPF patients,” said Philippe Wiesel, Chief Medical Officer at Agomab. “We believe that by blocking the TGFβ/ALK5 pathway locally in the lung, AGMB-447 has the potential to offer a potent anti-fibrotic therapy to IPF patients. The extensive data collected in our broad Phase 1 program supports the initiation of our Phase 2 INSPIRIA study later this year.”

The company also announced the design of INSPIRIA, its planned Phase 2 study with AGMB-447 in IPF. INSPIRIA is a 24-week Phase 2, randomized, double-blind, placebo-controlled study in approximately 120 patients with confirmed IPF. Patients will be randomized 2:1 to receive AGMB-447 4 mg twice daily or placebo, administered by inhalation on top of standard of care. The study is designed to evaluate the safety, pharmacokinetics and efficacy of AGMB-447 in IPF patients. The primary endpoint will be the change from baseline in forced vital capacity at Week 24. The CTA for INSPIRIA has been submitted, and the study is anticipated to begin in the second half of 2026 across a large European site network.

“We have long known that the TGFβ pathway is a central driver of fibrosis in IPF. Targeting this key pathway through ALK5 inhibition with AGMB-447 is a promising approach. With a convenient twice-daily dosing schedule, AGMB-447 could represent an attractive option for monotherapy or combination therapy with systemic standard of care therapies. The INSPIRIA study is designed to further explore the therapeutic potential of this novel inhaled approach in people living with IPF,” said Toby Maher, M.D., PhD, Professor of Clinical Medicine at Keck School of Medicine of USC.

Agomab intends to present detailed Phase 1 results at a future scientific conference.

AGMB-447 is an investigational drug and not approved by any regulatory authority. Its efficacy and safety have not been established. 

About IPF
Idiopathic Pulmonary Fibrosis (IPF) is a devastating disease affecting approximately 255,000 patients in the U.S., Japan, and the largest European markets (EU4+UK). IPF is characterized by unregulated production of fibrotic, scar-like tissue that builds up in the scaffolding of the lungs. As a result, the fibrotic lung becomes stiff, hampers the patient’s ability to breathe and reduces the absorption of inhaled oxygen in the blood. Despite the commercial availability of three approved therapies, without a lung transplant, the median survival following diagnosis is only 3-5 years. Moreover, these therapies do not halt but only slow down disease progression and have side effects that reduce tolerability and lead to treatment discontinuations.

About AGMB-447
AGMB-447 is an inhaled lung-restricted small molecule inhibitor of ALK5 (or TGFβR1) intended for the treatment of Idiopathic Pulmonary Fibrosis (IPF). TGFβ is the master regulator of fibrosis, which is the key mechanism driving IPF disease progression. AGMB-447 is specifically designed to inhibit ALK5 in the lung while avoiding clinically relevant systemic exposure through local administration via inhalation and rapid hydrolyzation in plasma into one main metabolite inactive in cells. Through AGMB-447, Agomab aims to offer a potentially safe and effective novel anti-fibrotic therapeutic option to IPF patients.

About Agomab
Agomab is a clinical-stage biopharmaceutical company focused on developing novel disease-modifying therapies for fibro-inflammatory diseases with high unmet medical need. Agomab’s product candidates are designed to target established, potent pathways and utilize organ-restricted approaches, with the aim of increasing efficacy while minimizing safety liabilities. Fostering a culture of excellence, Agomab’s mission is to pioneer therapeutics that aim to resolve fibro-inflammation and restore organ function to enable people with these disorders to live fuller and healthier lives.

Cautionary Note regarding Forward-Looking Statements
This press release includes certain disclosures that contain “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements are often identified by terms such as “continue,” “anticipate,” “believe,” “could,” “estimate,” “expect,” “goal,” “intend,” “look forward to,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “will,” “would” and similar expressions. “Forward-looking statements” include, without limitation, statements regarding the potential of AGMB-447 for the treatment of IPF, the design of the planned Phase 2 clinical trial with AGMB-447 for IPF, our expectation to initiate our Phase 2 clinical trial of AGMB-447 in IPF in the second half of 2026, and our interactions with regulatory authorities. Forward-looking statements are based on Agomab’s current expectations and are subject to inherent uncertainties, risks and assumptions that are difficult to predict. Factors that could cause actual results to differ include, but are not limited to, risks and uncertainties related to the results of our clinical trials; expectations regarding the inherent uncertainties associated with the development of novel drug therapies; preclinical and clinical trial and product development activities and regulatory approval requirements for product candidates; the impact of governmental laws and regulations on our business; and disruptions caused by our reliance on third party suppliers and service providers. These and other risks and uncertainties are described more fully in our filings and reports with the SEC, including in our most recent annual report on Form 20‐F filed with the SEC and our subsequent filings and reports filed with the SEC. Forward-looking statements contained in this announcement are made as of this date, and Agomab undertakes no duty to update such information except as required under applicable law. Readers should not rely upon the information in this announcement as current or accurate after its publication date.

Contacts
Investors
Sofie Van Gijsel
VP of Investor Relations
E-Mail: sofie.vangijsel@agomab.com
Phone: +1 781 296 1143
        
Media
Gretchen Schweitzer
Trophic Communications
E-Mail: agomab@trophic.eu 
Phone: +49 172 861 8540


1 Study Details | Phase I Study to Assess Safety, Tolerability, PK and PD of AGMB-447 in Healthy Participants and Participants With IPF | ClinicalTrials.gov

Collaboration to evaluate MicronJet™ with NurExone exosomes across ophthalmic and aesthetic applications in multi-billion-dollar markets

TORONTO and HAIFA, Israel, Sept. 14, 2026 (GLOBE NEWSWIRE) — NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (FSE: J90) (“NurExone” or the “Company”), a biopharmaceutical company developing exosome-based regenerative therapies, announces that its Israeli subsidiary, NurExone Biologic Ltd., has entered into a Memorandum of Understanding (the “MOU”) with NanoPass Technologies Ltd. (“NanoPass”), a medical device company specializing in precision delivery, to evaluate the integration of NanoPass’s MicronJet™ platform with NurExone’s exosome formulations for eye and skin applications.

NurExone’s exosomes are designed to act as biological delivery vehicles, targeting damaged tissue either on their own or carrying therapeutic cargo. NanoPass’s FDA-cleared MicronJet™ intradermal delivery platform provides precise, controlled and safe placement at the site of administration (leveraging advanced MEMS technology silicon-crystal pyramids).

Ophthalmology

NurExone is developing ExoPTEN for optic nerve damage, including glaucoma-related indications, following preclinical studies showing improvements in retinal function and retinal ganglion cell survival compared with controls.

The companies plan to evaluate NanoPass’s MicronJet™ technology for suprachoroidal delivery in a preclinical study comparing it with existing administration methods. The study will assess whether NanoPass’s platform can provide a practical, minimally invasive and consistent administration method that could support future clinical use, scale-up and commercialization. Precise delivery is important in the eye, and the suprachoroidal space offers a way to place treatment close to the retina and optic nerve while limiting exposure to other parts of the eye.

Dermatology and Aesthetics

The companies also plan to evaluate the use of MicronJet™ for intradermal delivery of NurExone’s exosome formulations for skincare and aesthetic applications.

A challenge in these applications is getting the exosomes beyond the skin’s natural barrier. Rather than remaining on the surface, NanoPass’s intradermal delivery technology is designed to place the formulation directly into the skin in a controlled and minimally invasive way.

For NurExone’s U.S. subsidiary, Exo-Top Inc., the collaboration could support development of an integrated exosome-and-delivery product that is straightforward for professional use and potentially easier to standardize and scale across applications such as skin rejuvenation and other aesthetic uses. The broader global regenerative aesthetics market is experiencing rapid expansion and is projected to grow from approximately US$17.7 billion in 2026 to approximately US$28.9 billion by 2030.1

Collaboration Terms

Under the MOU, the companies will evaluate NanoPass’s MicronJet™ platform with NurExone’s MSC-derived exosome formulations. Each party will fund its own activities; NurExone will own the preclinical proof-of-concept results, with newly developed IP jointly owned.

CEO Commentaries

“Our exosome platform is designed to work across multiple indications, and NanoPass gives us an opportunity to test an additional administration approach where localized delivery may be especially useful,” said Dr. Lior Shaltiel, Chief Executive Officer of NurExone. “For eye and skin applications, we will evaluate whether the combination can create a practical, consistent and easy-to-use product format for future clinical and commercial use. ExoPTEN’s acute spinal cord injury program is advancing through a separate minimally invasive administration approach.”

“Exosomes are emerging as an important new class of biological products, and we believe they represent a significant new opportunity for our delivery platform,” said Daniel Levitats, Chief Executive Officer of NanoPass Technologies. “NurExone gives us the opportunity to evaluate MicronJet™ across both therapeutic and commercial exosome applications and potentially establish a new area of use for a technology already supported by extensive clinical experience.”

The MOU does not obligate either party to enter into a definitive commercial agreement and may be terminated by either party without cause on 30 days’ written notice. The full details of the collaboration agreement and the Company’s ongoing corporate and financial roadmaps can be accessed by visiting the Company’s website at www.nurexone.com and its SEDAR+ profile at www.sedarplus.ca.

About NanoPass Technologies Ltd.

NanoPass Technologies Ltd. is a global medical device company pioneering precision intradermal drug delivery. The company developed MicronJet™, the first FDA-cleared device specifically designed for true intradermal delivery (<1 mm), enabling accurate, consistent, and safe delivery into the dermis.

Supported by over 70 clinical studies and millions of successful treatments worldwide, NanoPass collaborates with pharmaceutical companies, researchers, and physicians all over the world to improve vaccine delivery, biologics administration, and regenerative aesthetic treatments.

Follow NanoPass on Linkedin, Instagram. Contact: info@nanopass.com

About NurExone

NurExone is a TSXV, OTCQB, and Frankfurt-listed biotech company focused on developing regenerative exosome-based therapies for central nervous system injuries. Its lead product, ExoPTEN, has demonstrated strong preclinical data supporting clinical potential in treating acute spinal cord and optic nerve damage. Regulatory milestones, including obtaining the Orphan Drug Designation, facilitate the Company’s roadmap towards clinical trials in the U.S. and Europe. Commercially, the Company is expected to offer solutions to companies interested in quality exosomes and minimally invasive targeted delivery for other indications. NurExone has established Exo-Top, a U.S. subsidiary, to anchor its North American activity and growth strategy.

For additional information and a brief interview, please watch Who is NurExone?, visit www.nurexone.com or follow NurExone on LinkedIn, Twitter, Facebook, or YouTube.

For more information, please contact:

Dr. Lior Shaltiel
Chief Executive Officer and Director
Phone: +972-52-4803034
Email: info@nurexone.com

Russo Partners LLC
Investor and Media Relations – United States
215 Park Ave S, Suite 1905
New York, NY 10003
Phone: 212-845-4200
Email: nurexone@russopartnersllc.com

Dr. Eva Reuter
Investor Relations – Germany
Phone: +49-69-1532-5857
Email: e.reuter@dr-reuter.eu

Neither the TSX Venture Exchange nor its Regulation Services Provider, as that term is defined in the policies of the TSX Venture Exchange, accepts responsibility for the adequacy or accuracy of this release.

FORWARD-LOOKING STATEMENTS

This press release contains “forward-looking information” and “forward-looking statements” within the meaning of applicable Canadian securities laws (collectively, “forward-looking statements”). Forward-looking statements are often, but not always, identified by words such as “may”, “will”, “should”, “could”, “expect”, “plan”, “intend”, “anticipate”, “believe”, “estimate”, “predict”, “potential” and similar expressions.

Forward-looking statements in this press release include, without limitation, statements relating to: the collaboration between NurExone and NanoPass; the planned evaluation of NanoPass’s MicronJet™ platform with NurExone’s exosome formulations; the timing, scope and results of planned preclinical studies; the potential use of the combined technologies in ophthalmic, dermatology, facial nerve and aesthetic applications; the potential for the collaboration to support future clinical development, scale-up, commercialization and integrated exosome products; the potential expansion of NanoPass’s platform into exosome-based applications; the potential benefits of precise and standardized administration; the expected continuation and advancement of NurExone’s acute spinal cord injury program; and the potential benefits of the non-shop and intellectual property arrangements under the MOU; the parties’ ability to carry out the contemplated work plans; and third-party projections regarding growth in the regenerative aesthetics market.

Forward-looking statements are based on management’s current expectations and assumptions as of the date of this press release, including assumptions regarding: the ability of the parties to carry out the planned evaluation and preclinical studies; the continued availability of capital, personnel, materials and third-party service providers on commercially reasonable terms; that the MicronJet™ platform will be compatible with NurExone’s exosome formulations; that preclinical results will support further development; that the parties will continue to cooperate under the terms of the MOU; that regulatory, manufacturing and commercial development activities will proceed as currently contemplated; and that market demand for exosome-based therapeutic and aesthetic applications will develop as anticipated.

Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to differ materially from those expressed or implied by such forward-looking statements, including, without limitation: early-stage development risk; the risk that planned studies may be delayed, modified or not completed; the risk that the MicronJet™ platform may not demonstrate the expected compatibility, delivery characteristics or development advantages with NurExone’s exosome formulations; the risk that preclinical results may not support further development or may not be predictive of clinical outcomes; regulatory review timing and outcomes; manufacturing, scale-up and commercialization risks; dependence on third-party collaborators, suppliers and counterparties; intellectual property risks; financing and market conditions; and the risks described in the Company’s continuous disclosure filings available under the Company’s SEDAR+ profile at www.sedarplus.ca. Readers are cautioned not to place undue reliance on forward-looking statements. Although the forward-looking statements contained in this press release are based on assumptions that management believes are reasonable as of the date hereof, actual results may differ materially. These forward-looking statements are made as of the date of this press release, and the Company undertakes no obligation to update or revise them except as required by applicable law.

1 The Business Research Company, Regenerative Aesthetics Global Market Report 2026 (February 12, 2026), available through Global Information, Inc. at https://www.giiresearch.com/report/tbrc1957739-regenerative-aesthetics-global-market-report.html

Post hoc analyses of SION-719 PreciSION CF subset showed a mean placebo-adjusted sweat chloride reduction of up to -8.6 mmol/L consistent with NBD1 biological activity

Dual combination Phase 2a trial expected to initiate in first quarter of 2027

46% workforce reduction and other cost-saving measures prioritize advancing the dual combination program and extend cash runway into the second half of 2029

Sionna to host conference call today at 4:30 p.m. ET

WALTHAM, Mass., Sept. 14, 2026 (GLOBE NEWSWIRE) — Sionna Therapeutics, Inc. (Nasdaq: SION), a clinical-stage biopharmaceutical company on a mission to develop novel medicines for cystic fibrosis (CF), today announced plans to advance SION-451 + SION-2222, its preferred proprietary dual combination, into the AscenSION CF Phase 2a proof-of-concept (POC) trial, and results from the company’s post hoc analysis of the PreciSION CF Phase 2a trial. The decision to advance SION-451 + SION-2222 follows an extensive review of clinical, pharmacokinetic (PK) and nonclinical data from PreciSION CF. Learnings from that trial and the previous Phase 1 dual combination trial will inform the development strategy for the dual combination.

“It was important for us to take the time to complete a comprehensive post hoc data analysis to better understand the SION-719 PreciSION CF trial results and their potential implications before determining the right path forward for our dual combination,” said Mike Cloonan, President and Chief Executive Officer of Sionna. “The analysis identified important factors that we believe complicated interpretation of the trial and may have blunted the impact of NBD1 stabilization. The post hoc findings, together with the favorable Phase 1 results for SION-451 + SION-2222, support advancing the dual combination into Phase 2a. We have been inspired by the CF community, whose voices continue to reinforce the need for new treatment options.”

“Despite the substantial progress made, there remains a significant need for new options for people with CF,” said Gregory S. Sawicki, M.D., M.P.H., Director of the Cystic Fibrosis Center at Boston Children’s Hospital and Associate Professor of Pediatrics at Harvard Medical School. “Directly stabilizing NBD1 continues to represent a differentiated approach to addressing the underlying biology of CF. I’m excited to see Sionna proceed with a Phase 2a trial of SION-451 + SION-2222, which will be an important next step in further exploring whether the NBD1 biology can translate into meaningful benefit for people with CF.”

Post Hoc Analysis of SION-719 PreciSION CF Phase 2a Clinical Trial
PreciSION CF Phase 2a (NCT07108153) was a randomized, double-blind, placebo-controlled, crossover trial that evaluated the safety and tolerability of SION-719 when added to Trikafta® in 15 adult participants with CF homozygous for F508del. Change in sweat chloride, an important measure of CFTR function, was the key activity endpoint. As previously announced, the trial did not achieve its key activity endpoint, and Sionna is not advancing SION-719 as an add-on to SOC.

Following the announcement of topline results, Sionna conducted a comprehensive analysis of the clinical, PK, and nonclinical data to better understand the PreciSION CF outcome, including implications for the NBD1 mechanism and the SION-451 + SION-2222 dual combination.

The primary analysis in the trial assessed placebo-adjusted sweat chloride change using Day 1 as baseline. A prespecified secondary analysis assessed placebo-adjusted sweat chloride change using the baseline measured at the start of each treatment period. Across the 14 evaluable participants, results were similar under both methodologies, with placebo-adjusted sweat chloride changes of -1.0 mmol/L in the primary analysis and -1.1 mmol/L in the secondary analysis.

The post hoc analysis identified three factors that may have confounded the observed treatment effect:

  • PK outliers: Three participants had drug exposures (one with SION-719 and two with the components of Trikafta (elexacaftor/tezacaftor/ivacaftor; ETI) at key timepoints consistent with non-adherence. Excluding these confounded participants resulted in mean placebo-adjusted sweat chloride change of -8.6 mmol/L using the secondary analysis of baseline measured at the start of each treatment period. The Company believes the secondary analysis to assess sweat chloride best accounts for variability observed between treatment periods.
  • Trikafta Exposure Levels: ETI exposures were lower during SION-719 treatment periods, with mean exposures of all three components declining by approximately 25-30% on average while remaining relatively stable during placebo periods.
  • CFTR Channel Biology: Post hoc analysis of preclinical CFHBE assay data suggests that the interaction between an NBD1 stabilizer, like SION-719, and a potentiator, like ivacaftor, may have blunted the additional benefit of NBD1 stabilization. This interaction is not observed when an NBD1 stabilizer is combined with complementary correctors targeting TMD1 or ICL4.

Sionna believes these analyses suggest that SION-719 was biologically active in the trial, but that PK outliers and complex interactions between SION-719 and Trikafta may have affected the observed outcome and blunted a potential treatment signal.

SION-451 + SION-2222 Dual Combination Phase 2 Development Plan
Sionna plans to advance SION-451 + SION-2222 into the AscenSION CF Phase 2a POC trial. The Company continues to believe that directly stabilizing NBD1 in combination with a complementary CFTR modulator has the potential to meaningfully improve CFTR function.

The AscenSION CF POC will be an open-label trial evaluating adults with CF homozygous for F508del treated with SION-451 + SION-2222 for 28 days. Participants will switch from Trikafta to SION-451 + SION-2222, and the trial will assess sweat chloride, safety, and PK. The design will incorporate key learnings from PreciSION CF with respect to dosing adherence and sweat chloride variability, and the trial is expected to initiate in the first quarter of 2027.

The decision to advance SION-451 + SION-2222 is supported by results from the Phase 1 healthy volunteer trial of SION-451-based dual combinations, for which the Company announced topline results on August 10, 2026. The trial achieved its safety, tolerability, and PK objectives. SION-451 + SION-2222 was identified as the preferred dual combination based on target exposure coverage, and the go-forward SION-451 twice daily (BID) + SION-2222 once daily (QD) regimen demonstrated a favorable tolerability profile. Phase 1 exposures of the planned doses were within the range associated with meaningful improvement in CFTR function in Sionna’s CFHBE assay.

Corporate Update
Following the completion of a comprehensive review of its operations, Sionna’s Board of Directors has approved a workforce reduction of approximately 46% and the Company has implemented other cost-saving measures to focus its resources on advancing SION-451 + SION-2222 and extend its operating runway. Sionna expects to retain the core clinical, scientific, regulatory, technical, and corporate capabilities required to advance the dual combination program. The Company currently estimates it will incur aggregate restructuring and related charges of approximately $6.4 million.

Sionna ended Q2 2026 with approximately $268.3 million in cash, cash equivalents, and marketable securities. The Company estimates that the workforce reduction, discontinuation of investment in SION-719 as an add-on to standard of care, and other cost-saving measures will extend its cash runway into the second half of 2029.

Webcast Details
Sionna Therapeutics’ live webcast will begin at 4:30 p.m. ET today, September 14th, 2026, and can be accessed via this link. Participants who prefer to listen via telephone, or ask a question, may register on Sionna’s Investor Relations website or by clicking here. A replay will be available on the “Events” page in the “Investors” section of Sionna’s website at https://investors.sionnatx.com/news-events/events.

About Sionna Therapeutics
Sionna Therapeutics is a clinical-stage biopharmaceutical company on a mission to revolutionize the current treatment paradigm for cystic fibrosis (CF) by developing novel medicines that normalize the function of the cystic fibrosis transmembrane conductance regulator (CFTR) protein. Sionna’s goal is to deliver differentiated medicines for people living with CF that can restore their CFTR function to as close to normal as possible by directly stabilizing CFTR’s nucleotide binding domain 1 (NBD1), which Sionna believes is central to potentially unlocking meaningful improvements in clinical outcomes and quality of life for people with CF. For more information about Sionna, visit www.sionnatx.com.

Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, without limitation, implied and express statements about Sionna’s beliefs and expectations regarding: its goal of transforming the treatment paradigm for CF; its interpretation of the results of the PreciSION CF trial and the impact of potential confounding factors on the interpretation of those results; the potential for NBD1 stabilization to improve CFTR function and produce clinical benefit, including beliefs about biological activity of SION-719 in PreciSION CF and the translatability of preclinical and in vitro assay data to clinical outcomes; the objectives, design, timing, initiation and conduct of a planned Phase 2a proof-of-concept trial of SION-451 + SION-2222; the therapeutic potential, clinical benefits and safety of SION-451 + SION-2222; the expected timing, scope, costs and benefits of the workforce reduction and other cost-saving measures; the Company’s ability to retain the capabilities and personnel needed to advance SION-451 + SION-2222 and operate as a public company; the Company’s expected cash runway; and other statements that are not historical facts.

In some cases, forward-looking statements can be identified by terms such as “may,” “will,” “should,” “would,” “expect,” “plan,” “anticipate,” “could,” “intend,” “target,” “project,” “believe,” “estimate,” “predict,” “potential” or “continue,” or the negative of these terms or other similar expressions. Any forward-looking statements are based on management’s current expectations and beliefs and are subject to risks, uncertainties and important factors that may cause actual events or results to differ materially, including uncertainties inherent in developing product candidates; interpreting the PreciSION CF results and potential confounding factors; the inherent limitations of post hoc analyses, which are exploratory and may not reliably predict future outcomes; the risk that in vitro and preclinical data may not translate to clinical benefit; the risk that results observed with one compound may not be predictive of results with a different compound or combination; and designing and conducting the planned Phase 2a trial. Additional risks include the Company’s ability to demonstrate that its candidates are safe and effective; obtain regulatory feedback or approvals; achieve anticipated restructuring savings and runway extension; retain key personnel and capabilities following the workforce reduction; secure sufficient funding; and respond to general economic, industry and market conditions. These risks and uncertainties are described in “Risk Factors” in Sionna’s most recent Quarterly Report on Form 10-Q and subsequent filings with the Securities and Exchange Commission. The events and circumstances reflected in the forward-looking statements may not be achieved or occur. Any forward-looking statements represent Sionna’s views only as of today and should not be relied upon as representing its views as of any subsequent date. Sionna disclaims any obligation to update any forward-looking statements except as required by law. No representations or warranties, express or implied, are made about the accuracy of any such forward-looking statements.

Media Contact
Sarah Spencer
media@sionnatx.com

Investor Contact
Juliet Labadorf
ir@sionnatx.com

KIRKLAND, Wash., Sept. 14, 2026 (GLOBE NEWSWIRE) — Kestra Medical Technologies, Ltd. (Nasdaq: KMTS), a leading wearable medical device and digital healthcare company, today reported financial results for the first quarter of fiscal year 2027, which ended July 31, 2026.

Financial Highlights

  • Generated revenue of $31.0 million in F1Q27, an increase of 60% compared to the prior year period.
  • Expanded gross margin to 56.5% in F1Q27 compared to 45.7% in the prior year period.
  • Increased FY27 revenue guidance to $141 million, representing growth of 48% compared to FY26.

“Kestra delivered another strong quarter of financial performance, generating revenue growth of 60% while expanding gross margin to over 56%,” said Brian Webster, President and CEO. “We remain confident that our focus on innovation and commercial expansion positions Kestra to generate durable, top-tier growth for years to come. Our team is executing on its commitments to prescribers and their patients and we believe this will continue to drive market expansion and advance Kestra on its path to market leadership.”

First Quarter Fiscal 2027 Financial Results

  • Total revenue was $31.0 million, an increase of 60% compared to the prior year period.
    • Revenue growth was driven by several factors, including wearable cardioverter defibrillator (WCD) market expansion, competitive share gains, new sales territories, higher mix of in-network patients, and ongoing improvements in revenue cycle management capabilities.
  • Gross profit was $17.5 million compared to $8.9 million in the prior year period.
    • Gross margin expanded to 56.5% compared to 45.7% in the prior year period, driven by volume leverage, a higher mix of in-network patients and execution of planned cost improvement programs.
  • GAAP operating expenses were $55.2 million compared to $37.7 million in the prior year period.
    • Excluding non-recurring costs and share-based compensation expense, adjusted operating expenses* were $44.2 million compared to $30.3 million in the prior year period. The increase was primarily attributable to growth in expenses related to the company’s commercial expansion and accelerated investment in key R&D programs.
  • GAAP net loss was $44.1 million compared to GAAP net loss of $25.8 million in the prior year period.
    • Adjusted EBITDA* loss was $24.0 million compared to an adjusted EBITDA loss of $19.4 million in the prior year period.
  • Cash and cash equivalents, and investments totaled $244.7 million as of July 31, 2026.
    • Including committed unused availability under the company’s term loan agreement, Kestra has total liquidity of approximately $320 million.

*Adjusted operating expenses and adjusted EBITDA are non-GAAP financial measures. See “Use of Non-GAAP Financial Measures” below for additional information. Reconciliations of adjusted operating expenses and adjusted EBITDA to the most directly comparable GAAP measure are included in this press release.

Fiscal Year 2027 Revenue Guidance
Kestra is increasing its FY27 revenue guidance to $141 million, representing growth of 48% compared to FY26. This compares to prior FY27 revenue guidance of $137 million.

Webcast and Conference Call
Kestra will host a conference call today at 4:30 p.m. Eastern Time to discuss financial results. A live and archived webcast of the event will be available in the “Events” section of the investor relations website.

About Kestra
Kestra Medical Technologies, Ltd. is a leading wearable medical device and digital healthcare company focused on transforming patient outcomes in cardiovascular disease using monitoring and therapeutic intervention technologies that are intuitive, intelligent, and connected. For more information, visit www.kestramedical.com.

Use of Non-GAAP Financial Measures
This press release contains certain financial information that is not presented in conformity with U.S. generally accepted accounting principles (“GAAP”), including adjusted operating expense and adjusted EBITDA. The non-GAAP financial measures are provided as supplemental information to Kestra’s financial measures presented in this press release that are calculated and presented in accordance with GAAP.

Adjusted operating expense is calculated as operating expenses, as adjusted to exclude share-based compensation expense and non-recurring expenses. Adjusted EBITDA is calculated as net income (loss), as adjusted to exclude other income/expense (including interest), income tax expense (benefit), depreciation and amortization expense, share-based compensation expense, and non-recurring expenses. Both metrics are presented because management believes they will allow investors to view Kestra’s performance in a manner similar to the method used by management to evaluate Kestra’s performance for both strategic and annual operating planning. Management believes that in order to properly understand short-term and long-term financial trends, it is helpful for investors to understand the impact of the items excluded from the calculation of adjusted operating expenses and adjusted EBITDA, in addition to considering Kestra’s GAAP financial measures. The excluded items vary in frequency and/or impact on our results of operations and management believes that the excluded items are not reflective of our ongoing core business operations and financial condition. Excluding such items allows investors and analysts to compare our operating performance to other companies in our industry and to compare our period-over-period results.

The non-GAAP financial measures used by Kestra may not be the same or calculated in the same manner as those used and calculated by other companies. Non-GAAP financial measures have limitations as analytical tools and should not be considered in isolation or as a substitute for Kestra’s financial results prepared and reported in accordance with GAAP. We urge investors to review the reconciliation of these non-GAAP financial measures to the comparable GAAP financial measures included in this press release, and not to rely on any single financial measure to evaluate our business. A reconciliation of adjusted operating expenses and adjusted EBITDA reported in this press release to the most comparable respective GAAP measure for the respective periods appears in the tables captioned “Reconciliation of GAAP Operating Expenses to Adjusted Operating Expenses” and “Reconciliation of GAAP Net Income (Loss) to Adjusted EBITDA” later in this release. Within the accompanying financial tables presented, certain columns and rows may not add due to the use of rounded numbers.

Forward-Looking Statements
Except where otherwise noted, the information contained in this press release is as of September 14, 2026. Statements in this press release and on the related teleconference that express a belief, expectation or intention, as well as those that are not historical fact, are forward-looking statements. Except as required by law, Kestra undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise. This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements about, among other topics, our anticipated operating and financial performance, including financial guidance and projections; business plans, strategy, goals and prospects, potential growth, and expectations for our products. Given their forward-looking nature, these statements involve substantial risks, uncertainties and potentially inaccurate assumptions, and we cannot ensure that any outcome expressed in these forward-looking statements will be realized in whole or in part. You can identify these statements by the fact that they use future dates or use words such as “will,” “may,” “could,” “likely,” “ongoing,” “continue,” “anticipate,” “estimate,” “expect,” “project,” “intend,” “plan,” “advance,” “remain,” “believe,” “assume,” “target,” “forecast,” “guidance,” “goal,” “objective,” “aim,” “seek,” “potential,” “hope” and other words and terms of similar meaning. Kestra’s financial guidance is based on estimates and assumptions that are subject to significant uncertainties. Among the factors that could cause actual results to differ materially from past results and future plans and projected future results are the following: risks related to our limited operating history and history of net losses; our ability to successfully achieve substantial market adoption of our products; competitive pressures; our ability to adapt our manufacturing and production capacities to evolving patterns of demand, governmental actions and customer trends; product defects or complaints and related liability; our ability to obtain and maintain adequate coverage and reimbursement levels for our products; our ability to comply with changing laws and regulatory requirements and resulting costs; our dependence on a limited number of suppliers; risks and uncertainties related to market conditions; and other risks and uncertainties, including those described under the heading “Risk Factors” in our Annual Report on Form 10-K for the fiscal year ended April 30, 2026 and other filings filed or to be filed with the U.S. Securities and Exchange Commission (“SEC”). These filings, when made, are available on the Investor Relations section of our website at https://investors.kestramedical.com/ and on the SEC’s website at https://sec.gov/.

KESTRA MEDICAL TECHNOLOGIES, LTD. AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS
(in thousands, except share and per share amounts)
(unaudited)

    Three Months Ended July 31,  
    2026     2025  
             
Revenue   $ 30,971     $ 19,371  
Cost of revenue     13,473       10,520  
Gross profit     17,498       8,851  
Operating expenses:            
Research and development     6,796       4,001  
Selling, general and administrative     48,359       33,728  
Total operating expenses     55,155       37,729  
Loss from operations     (37,657 )     (28,878 )
Other expense (income):            
Interest expense     1,929       1,912  
Interest income     (2,125 )     (2,167 )
Other expense (income), net     272       (2,830 )
Loss on extinguishment of debt     6,304       —  
Net loss before provision for income taxes     (44,037 )     (25,793 )
Provision for income taxes     50       33  
Net loss attributable to common shareholders, basic and diluted   $ (44,087 )   $ (25,826 )
             
Net loss per share attributable to common shareholders, basic and diluted   $ (0.75 )   $ (0.50 )
Weighted-average common shares outstanding, basic and diluted     58,566,467       51,304,599  
             
Other comprehensive loss:            
Net loss   $ (44,087 )   $ (25,826 )
Unrealized loss on marketable securities     (253 )   —  
Comprehensive loss   $ (44,340 )   $ (25,826 )

KESTRA MEDICAL TECHNOLOGIES, LTD. AND SUBSIDIARIES
CONSOLIDATED BALANCE SHEETS
(in thousands, except share and per share amounts)
(unaudited)

    July 31,     April 30,  
    2026     2026  
             
Assets            
Current assets            
Cash and cash equivalents   $ 68,558     $ 99,710  
Short-term investments     130,353     $ 96,724  
Accounts receivable, net     15,406       14,542  
Disposable medical equipment supplies     7,438       6,706  
Prepaid expenses and other current assets     4,518       4,677  
Total current assets     226,273       222,359  
             
Long-term investments     45,791       65,767  
Right-of-use assets     3,263       3,364  
Deposits     1,842       1,761  
Restricted cash     334       334  
Property and equipment, net     63,656       59,090  
Other long-term assets     6,196       5,790  
Total assets   $ 347,355     $ 358,465  
             
Liabilities and Shareholders’ Equity            
Current liabilities            
Accounts payable   $ 25,961     $ 27,295  
Accrued liabilities     22,285       23,046  
Operating lease liabilities, current portion     23       31  
Total current liabilities     48,269       50,372  
             
Operating lease liabilities, net of current portion     3,928       4,111  
Warrant liabilities   —       1,369  
Other long-term liabilities     306       306  
Long-term debt, net     72,495       42,649  
Total liabilities     124,998       98,807  
             
Commitments and contingencies            
             
Shareholders’ equity            
             
Common Shares, $1.00 par value; 100,000,000 shares authorized as of July 31, 2026 and April 30, 2026; 59,271,885 issued and outstanding as of July 31, 2026 and 58,383,924 shares issued and outstanding as of April 30, 2026     59,272       58,384  
Additional paid-in capital     859,504       853,353  
Accumulated other comprehensive loss     (471 )     (218 )
Accumulated deficit     (695,948 )     (651,861 )
Total shareholders’ equity     222,357       259,658  
Total liabilities and shareholders’ equity   $ 347,355     $ 358,465  

KESTRA MEDICAL TECHNOLOGIES, LTD. AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF CASH FLOWS
(in thousands)
(unaudited)

    Three Months Ended July 31,  
    2026     2025  
Cash flows from operating activities            
Net loss   $ (44,087 )   $ (25,826 )
Adjustments to reconcile net loss to net cash used in operating activities:            
Depreciation and amortization     2,664       2,028  
Loss on disposal of property and equipment     292       280  
Reserve for equipment and supplies     1,464       412  
(Recovery) provision for uncollectible accounts receivable     (817 )     613  
Amortization (accretion) of premiums (discounts) on securities, net     (890 )   —  
Loss on extinguishment of debt     6,304     —  
Amortization of debt discounts and issuance costs     408       469  
Share-based compensation expense     9,517       4,579  
Non-cash lease expense     103       61  
Change in fair value of warrant liabilities     251       (2,909 )
Changes in operating assets and liabilities:            
Disposable medical equipment supplies     (908 )     (460 )
Prepaid expenses and other current assets     246       140  
Accounts receivable     (48 )     (1,777 )
Accounts payable     (1,879 )     (2,896 )
Accrued liabilities     (4,727 )     (860 )
Operating lease liabilities     (190 )     (138 )
Other long-term assets     2       10  
Net cash used in operating activities     (32,295 )     (26,274 )
Cash flows from investing activities            
Purchases of property and equipment     (8,335 )     (8,166 )
Deposits for medical rental equipment   —       (103 )
Refund of deposits for medical rental equipment   —       37  
Purchase of marketable securities     (13,017 )     —  
Net cash used in investing activities     (21,352 )     (8,232 )
Cash flows from financing activities            
Proceeds from issuance of long-term debt     75,000     —  
Payment of debt issuance costs     (3,193 )   —  
Repayment of long-term debt     (46,395 )   —  
Payment of early termination fee on debt repayment     (3,758 )      
Payment of IPO offering costs     —       (1,875 )
Payment of equity issuance costs     (415 )   —  
Deemed dividend for payments to third party on behalf of shareholder     (172 )   —  
Proceeds from stock option exercises     1,140     —  
Proceeds from Employee Stock Purchase Plan     1,298     —  
Tax withholdings on restricted stock unit vesting     (1,010 )   —  
Net cash provided by (used in) financing activities     22,495       (1,875 )
Net decrease in cash, cash equivalents and restricted cash     (31,152 )     (36,381 )
Cash, cash equivalents and restricted cash            
Beginning of period     100,044       237,929  
End of period   $ 68,892     $ 201,548  

RECONCILIATION OF CASH AND CASH EQUIVALENTS TO CASH, CASH EQUIVALENTS, AND INVESTMENTS
(in thousands)
(unaudited)

    Three Months Ended July 31,  
    2026     2025  
Cash and cash equivalents   $ 68,558     $ 201,214  
Add: Short-term investments     130,353     —  
Add: Long-term investments     45,791     —  
Cash, cash equivalents, and investments   $ 244,702     $ 201,214  

RECONCILIATION OF GAAP NET LOSS TO ADJUSTED EBITDA
(in thousands)
(unaudited)

    Three Months Ended July 31,  
    2026     2025  
             
GAAP Net loss   $ (44,087 )   $ (25,826 )
Non-GAAP Adjustments:            
Interest expense     1,929       1,912  
Interest income     (2,125 )     (2,167 )
Other expense (income)     272       (2,830 )
Provision for income taxes     50       33  
Depreciation expense     2,664       2,028  
Share-based compensation expense     9,517       4,579  
Loss on extinguishment of debt     6,304       —  
Non-recurring expenses     1,430       2,866  
Adjusted EBITDA   $ (24,046 )   $ (19,405 )

RECONCILIATION OF GAAP OPERATING EXPENSES TO ADJUSTED OPERATING EXPENSES
(in thousands)
(unaudited)

    Three Months Ended July 31,  
    2026     2025  
             
GAAP Operating Expenses   $ 55,155     $ 37,729  
Non-GAAP Adjustments:            
Share-based compensation expense     9,517       4,579  
Non-recurring expenses     1,430       2,866  
Adjusted Operating Expenses   $ 44,208     $ 30,284  
CONTACT: Investor Relations
Neil Bhalodkar
neil.bhalodkar@kestramedical.com

Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.